The effect of estrogen replacement on early Parkinson’s disease

Saunders‐Pullman, Rachel; Gordon-Elliott, Janna; Parides, Michael K.; Fahn, Stanley; Saunders, H.R.; Bressman, Susan

doi:10.1212/wnl.52.7.1417

Cited by 244 publications

(164 citation statements)

References 20 publications

Supporting

Mentioning

155

Contrasting

Unclassified

Order By: Relevance

“…A number of differences in nigrostriatal DA response to estrogen have been reported as a function of the time/duration of estrogen exposure (Hruska 1986;Fernandez-Ruiz et al 1989), the differential site of 6-OHDA administered or the dose of 6-OHDA used (Ferraz et al 2003). It is worth noting that a retrospective chart review showed that estrogen might be beneficial in early PD, at least prior to the initiation of L-dopa (Saunders-Pullman et al 1999). In our present study, we chose the lowest efficient dose of EB for detecting the possible effects of estrogen on the amygdala of PD model rats.…”

Section: Discussionmentioning

confidence: 99%

Increased dopamine release in vivo by estradiol benzoate from the central amygdaloid nucleus of Parkinson's disease model rats

Liu

Xie

2004

Journal of Neurochemistry

View full text Add to dashboard Cite

In addition to the dopaminergic neurons in the nigrostriatal system, the properties of dopaminergic neurons in the mesolimbic system, such as the amygdala, are also of interest and importance because of their specific neuromodulatory effects in the pathophysiology of Parkinson's disease (PD). Using the fast cyclic voltammetry (FCV) technique, we present evidence to indicate that electrically-evoked dopamine (DA) release from the amygdala, especially the central amygdaloid nucleus (CAN), of ovariectomized (OVX) female rats was significantly enhanced with increasing doses of estradiol benzoate (EB; 30, 50 and 100 lg/kg). Impaired DA release from the amygdala of an OVX rat PD model can also be increased by EB treatment (50 lg/kg) to a level similar to that of controls. The well established neuroprotective effects of estrogen may be beneficial for reducing the dysfunction of dopaminergic neurons in mesolimbic structures of rat PD models and PD patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Increased dopamine release in vivo by estradiol benzoate from the central amygdaloid nucleus of Parkinson's disease model rats

Liu

Xie

2004

Journal of Neurochemistry

View full text Add to dashboard Cite

show abstract

“…Additionally, postmenopausal estrogen treatment has been reported to retard PD progression [645,646]. A small case-control study reported increased risk of PD associated with hysterectomy (OR 3.36, 95% CI 1.05-10.77), but no associations for age at menopause or use of postmenopausal estrogens [647].…”

Section: Estrogenmentioning

confidence: 99%

Epidemiology and etiology of Parkinson’s disease: a review of the evidence

et al. 2011

View full text Add to dashboard Cite

show abstract

“…17␤-estradiol was reported to protect against NMDAinduced excitotoxicity by direct inhibition of NMDA receptors (Weaver et al 1997) and recently, a positive association was reported between estrogen use and a lower symptom severity in women with early Parkinson disease no yet taking L-Dopa (Saunders-Pullman et al 1999).…”

Section: Nmda Receptors Mrna Levelsmentioning

confidence: 99%

Estrogen-like Activity of Tamoxifen and Raloxifene on NMDA Receptor Binding and Expression of its Subunits in Rat Brain

Cyr

Thibault

Morissette

et al. 2001

Neuropsychopharmacology

View full text Add to dashboard Cite

Hormonal specificity of modulation of N-methyl-D-aspartate (NMDA) receptors was investigated by comparing the effects of estradiol with tamoxifen or raloxifene, which display different responses in breast, bone, and uterus. Two weeks ovariectomy in rats decreasedIt has been shown that the female sex steroid estradiol exerts profound effects on neuronal differentiation during development (Toran-Allerand et al. 1983) and recently, accumulating evidence support also a modulatory role of estrogens in the normal maintenance of brain function during aging (Simpkins et al. 1994). Beneficial effects of estradiol in mood disorders (i.e., depression, pre-menstrual syndrome, post-natal depression), as well as mental diseases, such as schizophrenia and Gille de la Tourette's syndrome, have been reported (Di Paolo 1994;Fink et al. 1998). Moreover, a beneficial role of estradiol in neurodegenerative disFrom the Oncology and Molecular Endocrinology Research Center, Laval University Medical Center, (CHUL), and Faculty of Pharmacy, Laval University, Sainte-Foy, Quebec, Canada, G1V 4G2.Address correspondence to: Dr. Thérèse Di Paolo, Oncology and Molecular Endocrinology Research Center, Laval University Medical Center, CHUQ, 2705, Laurier Boulevard, Sainte-Foy, Quebec, Canada G1V 4G2.Received July 5, 2000; revised December 20, 2000; accepted January 3, 2001. N EUROPSYCHOPHARMACOLOGY 2001 -VOL . 25 , NO . 2 SERMs Modulate NMDA Receptors 243 eases, such as Alzheimer has been recently suggested (Tang et al. 1996;Henderson 1997;Inestrosa et al. 1998). However, the mechanisms by which these effects of estrogens are yet to be fully characterized. N-methyl-D-aspartate (NMDA) receptors, a subtype of ionotropic glutamate receptor, have been implicated, as mediators, in some effects of estradiol on morphological plasticity and related physiological and cognitive processes in the brain (Moriyoshi et al. 1991). However, only few studies have directly investigated the role of estradiol in regulating NMDA receptors in rat and, in addition, these studies have focused on the effects of estradiol on hippocampal NMDA receptors (Woolley and McEwen 1992;Gazzaley et al. 1996;Woolley et al. 1997). We have recently investigated the effects of estradiol on the NMDA receptors agonist sites in brain regions implicated in mental disorders, such as frontal cortex, striatum, and nucleus accumbens (Cyr et al. 2000a). Our experiments showed that ovariectomy, as well as estradiol have regional specific effects since, for example, ovariectomy decreases NMDA receptor specific binding in hippocampal CA1 and dentate gyrus regions, whereas it has no effect in frontal cortex. In contrast, estradiol increases NMDA specific binding in the hippocampal CA1 and the dentate gyrus, but it decreases this binding in the frontal cortex (Cyr et al. 2000a).The present study sought to determine whether changes observed previously at the protein level after hormonal withdrawal due to ovariectomy or after estradiol treatment reflect changes at the level of gene transcription...

show abstract

The effect of estrogen replacement on early Parkinson’s disease

Abstract: We found a positive association between estrogen use and lower symptom severity in women with early PD not yet taking L-dopa. These results indicate that estrogen therapy should not be avoided and may be beneficial in early PD, at least prior to the initiation of L-dopa.

Cited by 244 publications

References 20 publications

Increased dopamine release in vivo by estradiol benzoate from the central amygdaloid nucleus of Parkinson's disease model rats

Increased dopamine release in vivo by estradiol benzoate from the central amygdaloid nucleus of Parkinson's disease model rats

Epidemiology and etiology of Parkinson’s disease: a review of the evidence

Estrogen-like Activity of Tamoxifen and Raloxifene on NMDA Receptor Binding and Expression of its Subunits in Rat Brain

Contact Info

Product

Resources

About